000			03929nam a22003615i 4500
001			80251
003			ES-MaUEC
005			20230207040258.0
007			cr nn 008mamaa
008			140206s2014 xxu| s |||| 0|eng d
020			_a9781461495604
024	7		_a10.1007/978-1-4614-9560-4 _2doi
050		4	_aRC647.C55 _bT443 2014
245	1	4	_aThe Coagulation Consult : _bA Case-Based Guide _cedited by Alan Lichtin, John Bartholomew.
260			_aNew York _bSpringer _c2014
300			_a1 recurso en línea (XII, 279 páginas) _b46 ilustraciones, 38 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aLaboratory Analysis of Coagulation -- Easy Bruisability -- Prolonged PT -- Prolonged PTT -- Prolongation of Both PT and aPTT -- Excessive Bleeding with Normal Prothrombin Time, Partial Thromboplastin Time, and Platelet Count -- Diagnosing Thrombocytopenia in the Clinic -- Thrombocytopenia in the Intensive Care Unit andÂ{u19B4}er Solid Organ Transplantation -- Thrombocytosis -- Prolonged Bleeding after Surgery -- The Excessively Clotting Cancer Patient -- Thrombotic Risk factors -- ClottingÂ{u1CAF}und Catheters and Other Devices -- Heparin-Induced Thrombocytopenia -- Surgery on Patients on Antiplatelet Agents -- Newer Oral Anticoagulants -- Pregnancy.
520	3		_aThere have been many changes in the field of coagulation during the past decade. New concepts of epidemiology of risk factors for thrombosis now help clinicians predict who is more likely to form clots after surgery, or after being placed on oral contraceptives. New anticoagulants have the potential to redefine how patients with atrial fibrillation and venous thrombosis are managed. There are new forms of recombinant clotting factors which have changed our approach to hypofibrinogenemia and von Willebrandâ€{u3824}isease. Newer antiplatelet agents are available and their use in patients receiving cardiac stents has mushroomed. The management of thrombosis in the setting of pregnancy has changed over the past decade, as well as the way clinicians approach women with multiple miscarriages. An entire new class of compounds, the thrombopoietins, are available to treat individuals with immune thrombocytopenic purpura (ITP). The Coagulation Consult covers major topics of interest to hematologists who are asked to consult on individuals with coagulation related diseases, and encompasses the fieldâ€{u382D}ost recent developments. This “case-directedâ€{u08AF}ok describes state-of-the-art approaches to patients with bleeding and clotting disorders, as well as laboratory tests for coagulation. Chapters include different vignettes, focus on typical clinical consult questions, and lay out specific types of treatment. Practicing clinicians being confronted with a coagulation consult, students, residents, fellows and attending physicians will find this unique text an invaluable resource for some of the newer areas of coagulation science, therapy and pharmacology.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, asignarmaterias, EBSPRINGER,
650		7	_aCoagulación sanguínea _2embne _9153305
650		7	_aCoagulación sanguínea _xTrastornos _2embne _9674461
700	1		_aLichtin, Alan _eeditor literario _988276 _0Local
700	1		_aBartholomew, John _eeditor literario _924507 _0comprobar BNE19970370921
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-9560-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12880048 _b10-10-17 _c11-11-15
998			_am _a_alco _a_vill _b11-11-15 _cm _dz _e- _feng _gxxu _h4
945			_aRC647.C55 T443 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1155986x _z06-04-17
999			_c80251 _d80251 _x1